Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on X:
“Pleased to share Nature reviews clinical oncology paper led by the amazing Jia (Jenny) Liu.
ADC responses can’t be predicted by target expression alone. Efficacy depends on antigen biology/ linker processing/ payload susceptibility, plus tumour microenvironment.
Our review proposes a modular framework covering each of these toxicity biomarkers, which have been largely overlooked.”
Title: A modular framework for antibody–drug conjugate biomarkers
Authors: Jia Liu, Dan-Yun Ruan, Nicholas McNamee, Roger R. Reddel, Hao-Xiang Wu, Qi Meng, Rui-Hua Xu, Vivek Subbiah, David L. Rimm, Barbara Pistilli
Read the Full Article on Nature reviews clinical oncology
You can also read: ADCs in GI Oncology: Current Clinical Evidence and Emerging Therapeutic Opportunities
Vivek Subbiah, Jia (Jenny) Liu
